Cyclerion Therapeutics, Inc. (CYCN)
Price:
1.50 USD
( - -0.18 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
NEWS
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call
seekingalpha.com
2025-09-24 12:53:50Cyclerion Therapeutics, Inc. - Pre Recorded Special Call Company Participants Regina Graul - CEO, President & Director Presentation Regina Graul CEO, President & Director Good morning, everyone. Yesterday, we announced Cyclerion's transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement that secures foundational intellectual property.
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
globenewswire.com
2025-09-23 16:01:00Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
globenewswire.com
2024-12-17 08:08:00CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth.
Regina Graul, Ph.D., Promoted to Chief Executive Officer
globenewswire.com
2024-08-07 07:00:00CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.
Cyclerion Appoints Regina Graul, Ph.D., as President
globenewswire.com
2023-12-04 08:00:00– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
globenewswire.com
2023-11-30 18:16:00- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
globenewswire.com
2023-07-31 07:00:00– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2022-08-09 18:48:09Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
benzinga.com
2022-06-17 11:27:03Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease. The data will be presented at the.
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
globenewswire.com
2022-06-06 07:00:00Topline results to be shared during the clinical trial update platform session
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
zacks.com
2021-12-15 11:35:17The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
seekingalpha.com
2021-10-26 16:29:42Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.
Trending Penny Stocks to Buy Now? 5 to Watch This Week
pennystocks.com
2021-10-24 14:30:00Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
globenewswire.com
2021-09-22 08:00:00Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit
globenewswire.com
2021-08-23 17:00:00Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
globenewswire.com
2021-07-29 17:00:00Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment
No data to display
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call
seekingalpha.com
2025-09-24 12:53:50Cyclerion Therapeutics, Inc. - Pre Recorded Special Call Company Participants Regina Graul - CEO, President & Director Presentation Regina Graul CEO, President & Director Good morning, everyone. Yesterday, we announced Cyclerion's transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement that secures foundational intellectual property.
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
globenewswire.com
2025-09-23 16:01:00Cyclerion has entered into a licensing agreement with MIT, securing the intellectual property that will serve as the cornerstone of its strategic relaunch.
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
globenewswire.com
2024-12-17 08:08:00CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth.
Regina Graul, Ph.D., Promoted to Chief Executive Officer
globenewswire.com
2024-08-07 07:00:00CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D.
Cyclerion Appoints Regina Graul, Ph.D., as President
globenewswire.com
2023-12-04 08:00:00– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
globenewswire.com
2023-11-30 18:16:00- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
globenewswire.com
2023-07-31 07:00:00– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
2022-08-09 18:48:09Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
benzinga.com
2022-06-17 11:27:03Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease. The data will be presented at the.
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium
globenewswire.com
2022-06-06 07:00:00Topline results to be shared during the clinical trial update platform session
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
zacks.com
2021-12-15 11:35:17The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
seekingalpha.com
2021-10-26 16:29:42Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.
Trending Penny Stocks to Buy Now? 5 to Watch This Week
pennystocks.com
2021-10-24 14:30:00Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
globenewswire.com
2021-09-22 08:00:00Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit
globenewswire.com
2021-08-23 17:00:00Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
globenewswire.com
2021-07-29 17:00:00Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment